T. Rowe Price Investment Management
ONC

T. Rowe Price Investment Management’s BeOne Medicines Ltd ONC Stock Holding History

T. Rowe Price Investment Management’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-143
Closed -$35K – 935
2025
Q2 		$35K Buy
+143
New +$35.1K ﹤0.01% 667

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Investment Management's ONC Position: Q3 2025 in Review

T. Rowe Price Investment Management sold out of BeOne Medicines Ltd (ONC) in Q3 2025, closing a stake of 143 shares — an estimated $35K sold.

T. Rowe Price Investment Management first reported a position in ONC in Q2 2025 and held it in 1 quarter. The position peaked at $35K in Q2 2025. 266 funds tracked by Wall St. Rank hold ONC as of Q3 2025.

  • T. Rowe Price Investment Management reported no remaining BeOne Medicines Ltd position as of Q3 2025 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 143 BeOne Medicines Ltd shares in Q3 2025, an estimated $35K.
  • T. Rowe Price Investment Management first reported a position in BeOne Medicines Ltd in Q2 2025 and held it in 1 quarter.
  • T. Rowe Price Investment Management's BeOne Medicines Ltd position peaked at $35K in Q2 2025.
  • 266 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q3 2025.

Based on T. Rowe Price Investment Management's 13F filing for Q3 2025, filed 14 Nov 2025.